Medicaid Is the Largest Behavioral Health Payer. A New Report Asks What Happens Next
Medicaid is the largest payer for behavioral health in the country. A new report asks what happens when psychedelic-assisted therapy reaches it. The answer is more complicated than approval followed by coverage. It came from the Center for Health Care Strategies and surfaced in Psychedelic Alpha’s September bulletin.
Cash pay economics look different the day a payer shows up. HealingMaps’ GPO, the first built for the ketamine industry, gets member clinics 40 percent or more off medical supplies, 15 to 20 percent off malpractice and liability premiums, discounted LegitScript certification, and 20 to 30 percent off HIPAA compliant payment processing. Joining is free with no obligation. See what your clinic qualifies for →
| Key Takeaway | Detail |
|---|---|
| The report | Psychedelic-Assisted Therapy and Medicaid: Considerations for Coverage and Access, published August 2026 |
| Who wrote it | Meryl Schulman, Logan Kelly and Allison Hamblin at the Center for Health Care Strategies |
| The partner | The Psychedelic Mental Health Access Alliance |
| The central claim | FDA approval and Medicaid coverage alone will not produce meaningful access |
| What is missing | Evidence, clinical guidelines, care models, sustainable payment, and a trained workforce |
| The detail for clinics | Some states already provide limited Medicaid access to off-label IV ketamine |
Why Medicaid Is the Number That Matters
Medicaid covers a large share of Americans with serious behavioral health conditions. It is the country’s largest behavioral health payer.
That makes it the difference between a treatment that exists and a treatment people can actually get. Commercial coverage sets a ceiling. Medicaid sets the floor.
It also covers the populations these therapies are studied in. Treatment-resistant depression, PTSD and substance use disorders.
The Report’s Central Argument
The authors make a point that cuts against the usual assumption in this field. Approval does not equal access, and neither does coverage.
Their list of what else is required is specific. Relevant evidence. Clinical guidelines. Practical care delivery models. Sustainable payment approaches. And a trained workforce integrated into safety-net settings.
You can read the full report from the Center for Health Care Strategies. It draws on stakeholder interviews rather than modeling.
Safety-Net Settings Are the Hard Part
That workforce point deserves attention. Clinics delivering this therapy today are almost entirely cash pay. They cluster in metros and are staffed by clinicians who sought the work out.
Safety-net settings are federally qualified health centers, community mental health centers and public systems. Different staffing, different reimbursement, different patient mix.
A model that works at 400 dollars a session in private practice does not transfer automatically. Our directory pricing analysis shows how far that sits from Medicaid rates.
The Line Most Operators Will Miss
The report notes that some states already provide limited Medicaid access to off-label intravenous ketamine.
That is worth reading twice. Not Spravato, which is FDA approved and has an established billing pathway. Off-label IV ketamine, under Medicaid, in some states, today.
If your practice sits in one of those states and treats only cash pay, ask your billing people about it this month. Not next year.
Spravato Is the Working Precedent
The report treats Spravato as the existing case. It is FDA approved for certain depressive disorders and it has coverage.
It is also the proof that a supervised psychiatric administration can be paid for at scale. Spravato reached 584 million dollars in a single quarter this year, up 40 percent.
We tracked that trajectory in our coverage of its growth. Whatever comes next will be reimbursed against that template, not invented from nothing.
This Is the Third Signal This Month
A federal report told states to start building licensing and oversight machinery. We covered it in our piece on the SAMHSA guidance.
The American Legion then backed a bill that would ban step therapy inside the VA. That is an explicitly reimbursement-focused provision, covered in our piece on the resolution.
Now the largest behavioral health payer is being studied for the same transition. Three different institutions preparing for coverage in the same four weeks is a pattern, not a coincidence.
What a Clinic Should Take From It
Nothing here changes billing tomorrow. No new code exists and no new coverage has been granted.
What it changes is the planning horizon. Practices built entirely around cash pay should understand that the payer conversation is now underway at the institutional level.
The operators who benefit first will be the ones already documenting outcomes, already credentialed, and already able to bill something. The IV ketamine approval pathway is the other route worth watching.
The Bottom Line
Coverage decisions determine scale in American medicine. Approval only determines whether scale is legal.
This report is the first serious look at how the largest behavioral health payer would absorb these treatments. Its conclusion is that coverage is necessary and nowhere near sufficient.
Patients looking for supervised care can start with our directory of verified ketamine clinics.
This article is for informational purposes and is not legal, billing or medical advice. Medicaid coverage policy varies by state. Confirm current rules with your state Medicaid agency.
